Nelson Advisors: Down Rounds, Bridge Rounds and Strategic Sales: HealthTech Founder's Honest Decision Tree for 2026
A pragmatic framework for later stage HealthTech founders facing the conversation nobody wants to have.
Founders talk to each other constantly about raising money. They compare term sheets, trade notes on which VCs move fast, debate SAFE caps versus priced rounds, and celebrate the closes on LinkedIn with the requisite rocket emoji. What they don't talk about nearly as often, what almost never gets a celebratory post, is the much more common set of conversations that later-stage HealthTech founders actually have in board meetings in 2026: whether to take a down round, whether to raise a bridge, or whether it's time to sell.
This is not an article about failure. That framing is precisely the problem. The venture industry has spent fifteen years selling founders a binary outcome set, become a unicorn, or don't matter and it has left an entire generation of operators without a real framework for the far more statistically likely middle path. The data from 2026 makes the shape of that middle path unusually clear. Capital is not gone from HealthTech; it is concentrated.
Rock Health's H1 2026 numbers show digital health companies raised $7.4 billion across 244 deals, which sounds healthy until you look at the distribution: just 19 companies closed 20 mega-deals of $100 million or more, and those deals alone absorbed 45% of all capital invested in the sector, up from 22% in 2024. Roughly 8% of deals swallowed nearly half the money. The median deal size, meanwhile, sits at $14 million, a perfectly reasonable Series A check, and a difficult number if you're a Series C company trying to defend a 2021 valuation.
That is the real story of HealthTech financing in 2026: a small number of category leaders are extraordinarily well funded, and everyone else is competing for a shrinking pool of "normal" capital with investors who have become considerably more disciplined about price. If you are a later-stage founder and the growth story that got you your last round has flattened, softened, or simply matured, you are not failing some unusual test. You are living inside a structural shift in how this market prices risk. The founders who navigate 2026 well are not the ones who deny that shift, they are the ones who build an honest decision framework for it before the runway forces their hand.
This article is that framework. It walks through the three paths, down round, bridge round and strategic sale. honestly: what each one actually is, when it is the right call, when it is a form of self-deception and how to make the decision deliberately rather than by default when the bank balance makes it for you.
Why 2026 Looks Different From 2021
It's worth being specific about what changed, because the instinct many founders have, "the market will loosen up, I just need six more months" is itself a strategic decision, and it deserves to be examined with the same rigour as any other.
Start with returns. Rock Health and Galen Growth data show the implied multiple-on-invested-capital for early-stage HealthTech bets has compressed sharply: Seed-stage MOIC fell from roughly 14.5x in the 2021 vintage to about 6.1x by 2025, and Series A returns more than halved over the same window. Investors read that compression the same way any allocator reads a falling return curve, they get pickier, they price risk more conservatively, and they stop treating "insider round to buy time" as a costless bridge to a better outcome. A venture investor who priced a Series B at a 2021 multiple is not eager to write a clean up-round check into a Series C that hasn't grown into that number. They will fund the company. They will just want a price that reflects 2026 reality, not 2021 enthusiasm and that is, definitionally, a down round.
Second, look at how long companies are actually taking to reach an exit. The median time from founding to exit has stretched from roughly seven years in 2022 to about 9.5 years in 2026. That's not a minor scheduling shift, it's an entire extra funding cycle that didn't used to exist in most founders' mental model of the business. If you raised your Series A in 2019 assuming a seven-year path to exit, you planned for an outcome around 2026. The market has quietly moved the goalposts to 2028 or 2029, and your cap table, your options pool, and your investors' fund life may not be built to absorb two extra years gracefully.
Third and this is the one that should reframe how every later-stage HealthTech founder thinks about the word "sale", the exit market itself has fundamentally shifted toward M&A. Across 2025 and into H1 2026, roughly 95% of digital health exits were acquisitions rather than IPOs; some trackers put the 2026 year-to-date figure as high as 99%. In H1 2026 alone, 115 acquisitions were announced in digital health, putting the year on pace to exceed 2025's 199 deals, with Q2 2026 posting the busiest quarter for announcements since Q3 2021, a lot of it concentrated in revenue cycle management, a sub-sector that has been consolidating hard.
Meanwhile the IPO window has all but closed: only Oura filed an S-1 in 2026, annual IPO volume hasn't come close to the 57 companies that went public in the 2021 peak, and the handful of digital health companies that have successfully listed in recent years typically did so with $100 million-plus in annual recurring revenue already in hand. GoHealth's Chapter 11 filing and Vicarious Surgical's delisting are useful, sobering reminders that the alternative to a well-timed strategic sale is sometimes not "staying independent" — it's a forced, much worse outcome later.
Put those three data points together and the picture is unambiguous. Later-stage HealthTech companies in 2026 are operating with longer timelines, pricier capital, and an exit market that runs almost entirely through acquisition rather than the public markets. A strategic sale isn't the consolation prize in this environment. Structurally, it is the primary exit mechanism for the overwhelming majority of successful HealthTech companies, which is exactly why treating it as a last resort, rather than a deliberate strategic option, is the single biggest mistake later-stage founders make.
The Decision Tree: Three Paths, Honestly Examined
Every later-stage founder facing a financing gap is implicitly choosing among three paths, whether or not they're doing it consciously: reprice and continue (a down round), extend and prove (a bridge round), or convert equity value into a transaction now (a strategic sale). Each path is the right answer under a specific, identifiable set of conditions, and each one becomes a mistake when it's chosen for the wrong reason, usually because it's the path that requires admitting the least, in the short term, about how the business is actually performing.
What follows is a honest walk through each path: the mechanics, the real trade-offs and the diagnostic questions that should determine which one you're actually looking at.
Path One: The Down Round
A down round means raising new capital at a valuation lower than your last priced round. Mechanically, it usually involves a new lead investor pricing the round, existing preferred shareholders facing dilution (and sometimes a "pay-to-play" provision that forces them to participate pro rata or lose anti-dilution protection and conversion rights), a broad-based weighted-average or full-ratchet anti-dilution adjustment kicking in for prior preferred series, and very often, a refresh of the option pool that further dilutes the common stock founders and employees hold. It is not simply "the same round at a lower number." It restructures who owns what, and it frequently restructures who controls what, since new investors negotiating from a position of leverage will often ask for stronger governance rights, board seats, or protective provisions than they would have gotten at a higher price in a more competitive process.
A down round is the right call when the underlying business is fundamentally sound but the price of the last round was simply wrong, a 2021-vintage valuation set in a market that has since repriced every comparable company in your category, while your retention, your gross margin trajectory, and your competitive position have held up or improved.
If your existing investors still believe in the business, have the capital and the fund life to support another round, and a new investor is willing to lead at a price that reflects current reality rather than aspirational multiples, a reset is often the cleanest way to give the company several more years of credible runway on a capital structure that isn't fighting the market. It is a decision about price, not about viability, and treating those two things as the same is where founders go wrong in both directions, some avoid a necessary reset out of pride, and others accept a reset as a substitute for fixing a business that has a deeper structural problem.
That's the failure mode worth naming directly: a down round used to avoid confronting a real problem, churn that's crept up, a regulatory pathway that's proven harder than expected, a competitor who has out-executed you on distribution, doesn't solve anything. It just moves the same conversation eighteen months down the road, at a lower price, with a more dilutive cap table, and with a board that now has less patience for a second reset. If you can't articulate specifically what will be structurally different about the business's trajectory after the new money lands, not "we'll grow faster" but a concrete, causally connected explanation of what changes, you are not fixing the price, you are delaying the diagnosis.
For founders heading into this conversation, three practical disciplines matter.
First, model the fully diluted cap table under the proposed terms before you accept a term sheet, including the anti-dilution mechanics for every prior series and any option pool refresh, the headline price per share tells you almost nothing about what you and your team will actually own afterward.
Second, negotiate the option pool size as its own line item, separately from the valuation discussion; investors will often bundle a large pool "shuffle" into the pre-money in a way that quietly shifts most of the dilution onto founders and employees rather than the new investor.
Third, get independent advice, from counsel and, ideally, a banker who has modelled these structures across multiple deals, rather than negotiating solely through the lens of your existing lead investor, whose interests in a down round (protecting their own prior mark, maintaining control) are not perfectly aligned with yours.
And be direct with your team. Employees will find out the valuation moved, whether from the option repricing, the funding announcement, or simply industry gossip. A founder who gets ahead of that conversation, explaining honestly why the reset happened and what it does and doesn't mean for the company's prospects, keeps far more trust, and far more of their best people, than one who lets the news arrive secondhand.
Path Two: The Bridge Round
A bridge round is smaller, faster, interim capital, typically structured as a convertible note or SAFE, sometimes layered with venture debt, designed to extend runway to a specific future milestone rather than to fund the next multi-year chapter of growth. It is very often insider-led, which is itself informative: existing investors writing a bridge check are making a bet that a near-term catalyst will materially change the company's valuation and they'd rather fund that catalyst cheaply now than wait for an outside investor to price it later at a premium they'd have to pay.
Used well, a bridge is one of the sharpest tools available to a later-stage founder. The test for "used well" is specific and unforgiving: is there a concrete, near-term, externally verifiable milestone, an FDA clearance decision, a signed payer contract, a major enterprise renewal, a clinical outcomes readout, that will plausibly and materially re-rate the company within the bridge's runway and is it genuinely credible that you'll hit it?
If you can name the milestone, name the date, and explain specifically why a new investor who says no today would say yes once that milestone lands, you are looking at a real bridge. Venture debt can be a useful complement here too, extending runway with less dilution than equity, but it comes with covenants, warrants, and often a lien on assets that turns a rough quarter into a much harder conversation with a lender who has different incentives than an equity investor. It should be sized and structured with the same rigor as any other financing decision, not treated as free money because it doesn't touch the cap table headline number.
The failure mode here has a name founders use quietly among themselves: the bridge to nowhere. This is a bridge raised not because a specific catalyst is close, but because the alternative, a hard conversation about a down round or a sale, is uncomfortable to have right now. It buys six to nine months, during which nothing structural actually changes about the business's trajectory, and it ends in the same conversation the founder was avoiding, except now with less cash, less goodwill, and a more complicated cap table, because bridge notes typically convert with a discount and a cap that stacks new liquidation preference ahead of everyone else, including, often, the founder's own economic interest in an eventual sale.
The honest diagnostic question is simple to state and hard to answer truthfully: what specifically will be different in six months that makes a new investor say yes when the current one just said no, or hesitated? If the answer is "we'll have more revenue" without a specific, credible driver behind that growth, or "the market will have improved," that is not a milestone, that is hope, and hope is not a financing strategy. If the answer is concrete and externally verifiable, structure the note carefully: keep the discount and cap disciplined rather than generous (a bridge priced too aggressively in the insiders' favour makes the eventual next round harder to close, since a new investor has to prices around that existing overhang), negotiate the maturity date and what happens contractually if the milestone isn't hit by then, and watch for most favoured nation clauses that can create awkward incentives among multiple bridge participants. And bring the board into this decision explicitly rather than letting it default through inertia, a bridge is very often where the tension between insider investors (who want to protect their prior mark) and the company's actual prospects surfaces most sharply, and a founder who names that tension directly, rather than letting it run silently underneath the decision, tends to get a cleaner outcome.
Path Three: The Strategic Sale
This is the path founders are most likely to treat as failure and least likely to plan for deliberately, which, given the 2026 exit data, is close to backwards. With M&A now accounting for somewhere between 95% and 99% of digital health exits, and IPO viability effectively restricted to a handful of category-defining companies with nine-figure ARR, a well-timed strategic sale is not the fallback option for later-stage HealthTech companies. Statistically, it is the primary mechanism by which successful HealthTech companies convert years of work into an actual outcome for their founders, employees, and investors.
A strategic sale can take several shapes worth distinguishing: a full acquisition of the company and its equity; an asset or technology acquisition, where a buyer wants the product, the data, or the IP but not the full corporate entity or its liabilities; an acquihire, where the primary asset a buyer values is the team; or a strategic investment that starts as a minority stake and is structured with a path toward eventual majority ownership or full acquisition. Each carries very different implications for founders and employees and conflating them, walking into a conversation assuming "acquisition" means one specific outcome, is a common and costly mistake.
The right time to sell is almost never when you're forced to. The single biggest determinant of outcome in a strategic sale isn't the quality of the underlying business in some abstract sense, it's leverage, and leverage is almost entirely a function of timing. A company that runs a sale process with twelve or more months of runway remaining, multiple relationships already warm with logical acquirers, and no immediate cash pressure will get a materially better price and better terms than the identical company running the same process with four months of runway left and one interested party who knows it. This is worth being blunt about because it cuts against founder instinct: the moment you should start building acquirer relationships is well before you need to sell, not after the board has concluded a sale is the only remaining option. Twelve to eighteen months of quiet relationship-building with three to five logical strategic acquirers, through partnership conversations, integration pilots, conference relationships, or simply staying visible in the categories those buyers are actively consolidating, is what creates real competitive tension in a process, even when only one buyer ultimately seems seriously interested. An advisor who has existing relationships across the relevant strategic and financial buyer universe can compress that timeline and create tension a founder running a solo process often can't, precisely because buyers behave differently when they believe they're one of several parties at the table rather than the only option a distressed seller has left.
It's also worth being explicit about the mid-market reality of HealthTech M&A, because it corrects a distortion that the loudest headlines create. The deals that get press attention are the outliers, the nine and ten-figure acquisitions of category leaders. But the overwhelming majority of HealthTech M&A activity happens in the lower-to-mid market, roughly the $25 million to $250 million enterprise value range, where strategic and private equity buyers are actively consolidating fragmented categories like revenue cycle management, remote patient monitoring, behavioral health technology, and clinical workflow automation. A founder who built a $40 million ARR business serving a defensible niche and sells it for a fair multiple in that range hasn't underperformed some imagined unicorn trajectory, they've executed the outcome that the actual data says is both the most common and, for most companies, the most achievable version of success in this market.
One more thing founders consistently underestimate: sale price and founder proceeds are not the same number, and the gap between them is determined by the liquidation preference stack that accumulated across every prior financing round, including any down round or bridge note that layered new preferred stock or converting debt ahead of common equity.
A founder walking into a sale conversation without having modelled the actual waterfall, who gets paid first, how much, and what's left for common stockholders and option holders after every preference stack is satisfied, can be genuinely surprised, at the worst possible moment, by how little of a headline sale price actually reaches them and their team. This is precisely why the earlier decisions in this framework, whether to take a down round, how a bridge note is structured, should never be made in isolation from their eventual effect on a sale outcome. Every dollar of new liquidation preference stacked on top of the company is a dollar that has to be cleared before common stockholders see anything, and founders who don't model that chain end up negotiating a sale from a much weaker position than the headline valuation suggests.
Walking the Tree: A Practical Framework
With all three paths examined honestly, the decision itself comes down to five diagnostic questions, asked in sequence and answered as honestly as the board conversation itself demands:
What is your actual runway at current burn, not projected burn? If you have twelve or more months of runway, you have the luxury of time to build acquirer relationships, negotiate from strength, and choose deliberately among all three paths. If you have six months or fewer, your option set has already narrowed, a full outside-led down round process typically takes three to six months to run properly, which means at six months of runway, a bridge or an accelerated sale process are often the only paths that are actually executable in time, whatever the "ideal" answer might otherwise be.
Is your core growth or retention metric improving, flat, or declining? A business that's still growing, even at a slower rate than 2021 expectations, with retention holding or improving, is a fundamentally different conversation than one where the core metric is actively eroding. The former supports a down round or a bridge toward a real catalyst; the latter usually means a sale, ideally sooner rather than later, while there's still a growth story, however modest, to sell.
Is there a specific, credible, near-term catalyst that would materially change how the market prices this business? If yes, and you can name it precisely, a bridge is worth seriously considering. If the honest answer is "not really, we'd just keep executing," a bridge is very likely a bridge to nowhere, and you should be looking at a down round or a sale process instead.
Do your existing investors have both the capital and the genuine will to keep funding you, at a price that reflects today's market? This is different from asking whether they like you or believe in the mission. Check fund life, check reserves, and have the direct conversation rather than assuming support that may not actually be there when a term sheet is on the table. A board that quietly doesn't have the appetite to lead or meaningfully participate in another round is signaling something founders often don't want to hear directly, that it may be time to build the acquirer relationships instead.
Is there a strategic buyer who needs what you have — your data, your distribution, your regulatory clearance, your team, more urgently than you need another round of capital? If the honest answer is yes, and especially if you have runway remaining to run a real process rather than a forced one, a strategic sale deserves to be evaluated as a primary option, not a last resort. Given that close to all digital health exits in 2026 run through M&A rather than the public markets, this is very often the answer that the data, rather than founder instinct, actually points toward.
Running through these five questions honestly, with your board, well before the runway forces a decision, is the single highest-leverage thing a later-stage HealthTech founder can do in this market. The founders who get the worst outcomes in 2026 are rarely the ones running businesses with the weakest fundamentals, they're the ones who let the calendar make the decision for them by avoiding this conversation until there was only one option left on the table.
What All Three Paths Have in Common
Whichever path fits, a few disciplines hold across all three, and they're worth naming explicitly because founders under pressure tend to skip them precisely when they matter most.
Talk to your board and lead investors early, and bring them real information rather than a filtered version of it. A board that's surprised by a cash crisis has every incentive to react defensively; a board that's been walked through the trend lines for two quarters running has time to actually help, whether that means opening doors to a bridge, a strategic buyer, or simply a more honest internal conversation about the path forward.
Get a current, defensible view of where the business actually stands before you assume you know your own valuation, markets move fast, and the number you raised at in 2021 or 2022 tells you very little about what a disciplined 2026 investor or acquirer will actually pay. Model your full cap table waterfall, including every liquidation preference and anti-dilution provision that's accumulated, before you negotiate anything, so you know precisely what any given outcome actually means for you, your co-founders, and your team, not just what the headline number implies.
Protect your team through honest, timely communication rather than reassurance you can't actually back up. Employees generally handle hard news about the business's trajectory far better than they handle finding out later that leadership knew and didn't say anything. And remember that your reputation as a founder outlasts any single company outcome, the way you handle a down round, a bridge, or a sale process is exactly what the next generation of investors, acquirers, and future team members will remember about how you operate under pressure. In a market this concentrated, where the same few hundred people make up the entire European HealthTech investor and acquirer universe, that reputation compounds in ways a single financing outcome never will.
The Path Forward
HealthTech has spent a decade telling founders there are two outcomes worth talking about: the unicorn and the write-off. The 2026 data tells a different, more useful story, one where the modal successful outcome for a later-stage HealthTech company is a disciplined repricing, a well-timed extension toward a real catalyst, or, more often than either, a strategic sale to a buyer who needs exactly what's been built. None of those outcomes are failure. They are what building a real company in a maturing, consolidating market actually looks like, and founders who plan for them deliberately, rather than treating them as conversations to avoid until the runway forces the issue, consistently land in a stronger position than those who don't.
If you're a later-stage HealthTech founder or a board member weighing exactly this decision, Nelson Advisors works with companies across this exact inflection point, modelling the cap table implications of a reset, structuring a bridge around a genuine catalyst, or building the quiet, well-timed process that turns a strategic sale into a strong outcome rather than a forced one. The earlier that conversation happens, the more options stay on the table.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments